https://doi.org/10.55788/ad7b43e9
“Over the past 2 decades, it has become increasingly clear that gout is an independent risk factor for increased mortality,” Dr Gregory Challener (Massachusetts General Hospital, MA, USA) stated [1]. Due to the growing interest in the question of whether tophaceous gout itself could be linked to a higher risk of mortality, a longitudinal cohort analysis investigated potential differences between the gout subgroups. Data for the multicentre study was collected from the US TriNetX Diamond network of claims records. Outcomes of mortality, acute MI, and ESRD were measured at years 1 and 5.
The tophaceous gout cohort included 73,569 patients and the non-tophaceous gout cohort 284,241. The mean age was about 67 years, over 50% were men, around 70% had hypertension, just over 25% had ischaemic heart disease, and 27.3–28.5% had chronic kidney disease. Before matching, significant differences existed between the cohorts for diabetes, obesity, and medication. “Following propensity score matching, all of these differences disappeared,” Dr Challener clarified.
At 1 year, the mortality risk for tophaceous gout versus non-tophaceous gout within the 2 matched groups was 5.0% versus 4.3%, leading to an HR of 1.20 (95% CI 1.15–1.26). After 5 years, the likelihood of mortality was 24% greater for patients with tophaceous gout (HR 1.24; 95% CI 1.20–1.27). Also, the chances for acute MI at 1 and 5 years were increased in the tophaceous gout group: HR 1.20 (95% CI 1.10–1.31) and HR 1.21 (95% CI 1.15–1.28), respectively. Kidney impairment in terms of ESRD followed a similar pattern: HR 1.12 (95% CI 1.02–1.24) at 1 year and HR 1.16 (95% CI 1.09–1.25) at 5 years. Dr Challener underlined that the results from the unmatched analysis were very similar.
Although this was a retrospective study, Dr Challener pointed out that it had strengths in its large population, multicentricity, and propensity score matching. “This result suggests that it is important to identify patients with tophaceous gout and to treat them aggressively, including with uricase treatment in those with an inadequate response on xanthine oxidase inhibitors,” Dr Challener concluded. The place for uricase therapy and its optimal use remains an area of ongoing research.
- Challener G, et al. Risk of mortality in patients with tophaceous versus non-tophaceous gout. OP0170, EULAR 2024 Congress, 12–15 June, Vienna, Austria.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Is JAK inhibition the right choice for patients with relapsing giant cell arteritis? Next Article
More patients hit their uric acid target with febuxostat and ruzinurad combination »
« Is JAK inhibition the right choice for patients with relapsing giant cell arteritis? Next Article
More patients hit their uric acid target with febuxostat and ruzinurad combination »
Table of Contents: EULAR 2024
Featured articles
Advanced therapies show promising results in PsA real-world study
Small protein targeting IL-17A effective in PsA management
Late-breaking Abstracts
Nipocalimab meets primary endpoint in Sjögren’s syndrome
Advanced therapies show promising results in PsA real-world study
Dual IL-17A/F blocker significantly reduces spinal radiographic progression in radiographic axSpA
Small protein targeting IL-17A effective in PsA management
Spotlight on Rheumatoid Arthritis
New JAK1 inhibitor outperforms placebo in active RA
Macrophage profiling in synovial tissue predicts treatment response in RA
Innovative app boosts mental health in patients with RA
What is New in Lupus and Scleroderma
Daratumumab shows promise in systemic lupus erythematosus
Severe lung involvement in SSc linked to anti-Ro/SSA antibodies
Early treatment with ambrisentan might prevent PAH development in patients with SSc
Crystal-related Disorders in 2024
More patients hit their uric acid target with febuxostat and ruzinurad combination
Tophaceous gout at higher mortality risk than non-tophaceous gout
JAK Inhibition in Giant Cell Arteritis
Is JAK inhibition the right choice for patients with relapsing giant cell arteritis?
Giant cell arteritis: Upadacitinib may be an upcoming treatment option
Spotlight on Other Indications
AxSpA: Higher comorbidity burden worsens radiographic progression
Hope for a durable effective injection therapy in knee osteoarthritis
Dermatomyositis: Triple therapy with tacrolimus beats cyclosporin regimen
Best of the Posters
Less fracture risk with denosumab than bisphosphonates in pre-treated osteoporosis
Low IL-18: a hidden culprit of long COVID in patients with autoimmune disease
Stopping DMARDs? These key factors predict RA flares
Related Articles
August 14, 2020
Low DAS at 4 months predicts sustained DMARD-free remission
February 4, 2020
Filgotinib promising in RA patients naïve to methotrexate
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com